AU2610799A - Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates - Google Patents

Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates

Info

Publication number
AU2610799A
AU2610799A AU26107/99A AU2610799A AU2610799A AU 2610799 A AU2610799 A AU 2610799A AU 26107/99 A AU26107/99 A AU 26107/99A AU 2610799 A AU2610799 A AU 2610799A AU 2610799 A AU2610799 A AU 2610799A
Authority
AU
Australia
Prior art keywords
glp
helix
aggregates
derivatives
per cent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26107/99A
Other languages
English (en)
Inventor
Soren Erik Bjorn
Per Olaf Huusfeldt
Niels C. Kaarsholm
Liselotte Bjerre Knudsen
Per Franklin Nielsen
Helle Birk Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2610799A publication Critical patent/AU2610799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Disintegrating Or Milling (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AU26107/99A 1998-02-27 1999-02-25 Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates Abandoned AU2610799A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK268/98 1998-02-27
DK272/98 1998-02-27
DK26898 1998-02-27
DK27298 1998-02-27
PCT/DK1999/000084 WO1999043341A1 (en) 1998-02-27 1999-02-25 Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Publications (1)

Publication Number Publication Date
AU2610799A true AU2610799A (en) 1999-09-15

Family

ID=26063652

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26107/99A Abandoned AU2610799A (en) 1998-02-27 1999-02-25 Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates

Country Status (6)

Country Link
EP (1) EP1061946B1 (https=)
JP (1) JP2002504518A (https=)
AT (1) ATE265224T1 (https=)
AU (1) AU2610799A (https=)
DE (1) DE69916811T2 (https=)
WO (1) WO1999043341A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
WO2001051071A2 (en) * 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
ES2253353T3 (es) 2000-03-08 2006-06-01 Novo Nordisk A/S Reduccion del colesterol serico.
JP4716641B2 (ja) 2000-06-16 2011-07-06 イーライ リリー アンド カンパニー グルカゴン様ペプチド−１類似体
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
AU2002322403A1 (en) 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
KR101198346B1 (ko) 2003-04-08 2012-11-06 노보 노르디스크 에이/에스 크로마토그래피 고정상의 재생
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
BR122019021416A2 (https=) * 2003-09-19 2019-12-21
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
RU2401276C2 (ru) * 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP1694278A4 (en) 2003-12-16 2009-08-12 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) * 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
MX2007005521A (es) 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
MX2012012383A (es) 2010-04-30 2012-11-30 Sanwa Kagaku Kenkyusho Co Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN115947849A (zh) 2018-12-21 2023-04-11 江苏恒瑞医药股份有限公司 双特异性蛋白
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
CN115461044B (zh) 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
EP4210680A1 (en) 2020-09-07 2023-07-19 Cyprumed GmbH Improved pharmaceutical formulations of glp-1 receptor agonists
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
JP2026502943A (ja) 2022-12-30 2026-01-27 アルギファルマ エーエス 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN116730902B (zh) * 2023-08-07 2023-11-21 杭州湃肽生化科技有限公司 一种合成利拉鲁肽的方法
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2583257B2 (ja) * 1986-05-05 1997-02-19 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン向性ホルモン
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
ATE193541T1 (de) * 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives

Also Published As

Publication number Publication date
ATE265224T1 (de) 2004-05-15
EP1061946B1 (en) 2004-04-28
DE69916811T2 (de) 2005-04-14
JP2002504518A (ja) 2002-02-12
DE69916811D1 (de) 2004-06-03
EP1061946A1 (en) 2000-12-27
WO1999043341A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
AU2610799A (en) Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
WO1999043361A8 (en) Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU6114699A (en) Naphthrydine compounds and their azaisosteric analogues as antibacterials
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
CA2325045A1 (en) Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
AU2959995A (en) Stereochemical wortmannin derivatives
HUP0003305A3 (en) Hiv protease inhibiting tetrahydro-pyrimid-2-on derivative, pharmaceutical compositions containing it and process for producing the compound
BG102836A (en) New benzazepine derivatives, medicamentous forms containing them, and their application for the preparation of medicaments
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
MY127953A (en) Gabapentin-containing solid compositions and process for preparing the same
AU4627097A (en) Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same
AU3031797A (en) New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
IL129616A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
HUT62585A (en) Process for producing 6-amino-octahydro-indolizinetriole derivatives and phqrmaceutical compositions comprising same as active ingredient
AU4925200A (en) Oral composition containing perlite
IL129627A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129625A0 (en) Novel (-)-enantionmers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU2596195A (en) Substituted alkyldiamine derivatives and their use as tachykinin antagonists
AU6832498A (en) Substituted benzyl oximino compounds
BG103986A (en) Derivatives of pyrrolidinecarboxylic acids as endotheline antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase